MedTrace Logo

Safety and Efficacy Study of Brimonidine in Patients With Glaucoma or Ocular Hypertension

NCT00652483 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 433

Last updated 2008-04-03

No results posted yet for this study

Summary

This study evaluates the safety and efficacy of brimonidine 0.1% ophthalmic solution compared with brimonidine 0.2% ophthalmic solution in patients with glaucoma or ocular hypertension

Conditions

Interventions

DRUG

Brimonidine ophthalmic solution 0.1%

1 drop instilled in each eye 3 times daily (08:00, 14:00, 20:00)

DRUG

Brimonidine ophthalmic solution 0.2%

1 drop instilled in each eye 3 times daily (08:00, 14:00, 20:00)

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Medical Director · Allergan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-05-31
Primary Completion
2003-12-31
Completion
2004-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00652483 on ClinicalTrials.gov